| Claudia Orellana, MD | |
|
4440 Viking Dr, Ste 300, Bossier City, LA 71111-7511 | |
| (318) 584-7137 | |
| (318) 584-7140 |
| Full Name | Claudia Orellana |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 18 Years |
| Location | 4440 Viking Dr, Bossier City, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417167842 | NPI | - | NPPES |
| 07927 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 200005 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ochsner Lsu Health Shreveport | Shreveport, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lsu Health Sciences Center Shreveport Faculty Group Practice | 4082902721 | 529 |
| Wk Center For Psychiatric Support | 6406972645 | 7 |
News Archive
The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.
Urgent changes are needed at the World Health Organization (WHO) to revitalise its role as global public-health agency
NYU Langone Medical Center has been recognized as a leading cardiovascular hospital in the United States. The medical center received the Thomson Reuters Top 50 Cardiovascular Hospitals 2012 Award for its high-quality cardiovascular care and excellent performance in key clinical measures. The medical center is the only hospital in New York State to be honored with this year's award.
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.
› Verified 3 days ago
| Entity Name | Wk Center For Psychiatric Support |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609194356 PECOS PAC ID: 6406972645 Enrollment ID: O20100925000006 |
News Archive
The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.
Urgent changes are needed at the World Health Organization (WHO) to revitalise its role as global public-health agency
NYU Langone Medical Center has been recognized as a leading cardiovascular hospital in the United States. The medical center received the Thomson Reuters Top 50 Cardiovascular Hospitals 2012 Award for its high-quality cardiovascular care and excellent performance in key clinical measures. The medical center is the only hospital in New York State to be honored with this year's award.
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.
› Verified 3 days ago
| Entity Name | Lsu Health Sciences Center Shreveport Faculty Group Practice |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013374222 PECOS PAC ID: 4082902721 Enrollment ID: O20161012000307 |
News Archive
The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.
Urgent changes are needed at the World Health Organization (WHO) to revitalise its role as global public-health agency
NYU Langone Medical Center has been recognized as a leading cardiovascular hospital in the United States. The medical center received the Thomson Reuters Top 50 Cardiovascular Hospitals 2012 Award for its high-quality cardiovascular care and excellent performance in key clinical measures. The medical center is the only hospital in New York State to be honored with this year's award.
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Claudia Orellana, MD 4440 Viking Dr, Ste 300, Bossier City, LA 71111-7511 Ph: (318) 584-7137 | Claudia Orellana, MD 4440 Viking Dr, Ste 300, Bossier City, LA 71111-7511 Ph: (318) 584-7137 |
News Archive
The U.S. Food and Drug Administration today approved Zelboraf (vemurafenib), a drug to treat patients with late-stage (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.
Urgent changes are needed at the World Health Organization (WHO) to revitalise its role as global public-health agency
NYU Langone Medical Center has been recognized as a leading cardiovascular hospital in the United States. The medical center received the Thomson Reuters Top 50 Cardiovascular Hospitals 2012 Award for its high-quality cardiovascular care and excellent performance in key clinical measures. The medical center is the only hospital in New York State to be honored with this year's award.
AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.
› Verified 3 days ago
Sanjeevi C. Tivakaran, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hospital Dr, Suite 220, Bossier City, LA 71111 Phone: 318-752-7840 Fax: 318-752-7845 | |
Dr. Sachin Babanao Thorat, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2400 Hospital Dr, Suite 310, Bossier City, LA 71111 Phone: 318-741-2900 Fax: 318-741-2999 | |
Lionel Guillaume, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3018 Old Minden Rd, Suite 1212, Bossier City, LA 71112 Phone: 318-747-1665 Fax: 318-747-1597 | |
Dr. Connie Hale, NP Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3018 Old Minden Rd Ste 1117, Bossier City, LA 71112 Phone: 318-746-1935 Fax: 318-746-2514 | |
Dr. Lee Stevens, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1007 Gould Dr Ste 1, Bossier City, LA 71111 Phone: 318-422-7154 Fax: 850-203-1448 |